Govit-19: Second generation vaccine, most effective in the long run, will soon be available in Toulouse

To live with Covit-19, the World Health Organization (WHO) is pushing for the development of second-generation vaccines that are long and effective in combating SARS-Cov 2 mutations. One of these solutions is Toulouse by GDP Bioways. The young company, formed in 2019, has partnered with the LinKinVax operating system to develop and manufacture the new Kovit-19 vaccine. The first clinical trials are expected next year.

Developed in November 2020, LinKinVax is based on the work of the Vaccine Research Institute (VRI), developed by the French National Agency for AIDS Research to accelerate the development of vaccines against HIV. “LinKinVax’s business is to provide innovative answers in the field of vaccination”, says Andre-Jack Aberton-Herv, co-founder and co-founder of LinKinVax, Pr Yves Lévy, Immunologist, Director of VRI and former Chairman of Inserm.

Long-term memory effect, easily distributed vaccine

For this vaccine, there is no question of messenger RNA. “Our vaccine is protein. A monoclonal antibody targets dendritic cells, the drones of the immune system. Like the authors, they teach how these cells respond to the immune system. Our technology will bring information to the recipient so that these authors will save time and performance and initiate a long lasting memory effect. We did not target the spike protein area, but the area less sensitive to viral mutations. Another advantage of the protein vaccine is that it is easy to prepare and distribute (preserved in a regular refrigerator or in frozen-dried form), “says Andre-Jack Aberton-Herv, who is pleased to be able to agree with a French subcontractor to manufacture medical packages.

GDP biowase works on the nasal vaccine

GTP Bioways has four bases, including a head office, a nano unit and a technology division in Toulouse and a site near Geneva (in partnership with the Farewa Group) for the production of antibodies. It employs 100 people with an income of 20 million euros a year and is already involved in developing the Nazi vaccine against Govt-19. “Our job is to create processes and produce them in the pharmaceutical environment. This is what we are going to do with the innovation that LinKinVax has come up with. The terminal bottles will be manufactured in Toulouse.